Gene therapy aims to stop painful swelling attacks in hereditary angioedema
NCT ID NCT05120830
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new treatment called NTLA-2002 for adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling attacks. The therapy uses gene editing to lower a protein that triggers these attacks. The goal is to see if it is safe and can reduce how often attacks happen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY ANGIOEDEMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Trial Site
Campbelltown, Australia
-
Clinical Trial Site
Grenoble, France
-
Clinical Trial Site
Lille, France
-
Clinical Trial Site
Paris, France
-
Clinical Trial Site
Berlin, Germany
-
Clinical Trial Site
Frankfurt, Germany
-
Clinical Trial Site
Amsterdam, Netherlands
-
Clinical Trial Site
Auckland, New Zealand
-
Clinical Trial Site
Cambridge, United Kingdom